The acquisition was entered in March 2018 and structured as a five-year deal with milestones.
KICVentures Group accelerated milestone payments to complete the acquisition within three years. The final milestone payment was made in September.
“With an accelerated closure of this acquisition, we are positioned to independently negotiate strategic partnerships and prepare the company for an IPO in three years,” Aditya Humad, CFO of KICVentures Group, said in a Dec. 23 news release.
NanoFuse Biologics is the developer of the only FDA-cleared bioactive glass and demineralized bone matrix combined device.
More articles on biologics:
‘Implementing new procedures can be scary’ — 4 spine surgeons offer tools for success
4 key trends in spine in 2021 — Access to care, outpatient migration & more
Mayo Clinic neurosurgeon featured in Netflix docuseries
